Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study

By Hill Simon   Elhilali Mostafa   Millard Richard J   Dwyer Peter L   Lheritier Karine   Kawakami Fernando T.   Steel Michael  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2697-2704

Informa Healthcare

Access to resources Recommend Favorite

Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week‐112 Efficacy and Safety Results of the Open‐Label Long‐Term Extension of a Phase III, Double‐Blind, Randomized, Placebo‐Controlled Trial

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 12, 2015-12 ,pp. : 1627-1636

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sequential erlotinib with gemcitabine in NSCLC

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 1, 2015-03 ,pp. : 4-14

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children

By Cañete Roberto   Escobedo Angel A.   González Maria Elena   Almirall Pedro   Cantelar Nereyda  

Current Medical Research and Opinion, Vol. 22, Iss. 11, 2006-11 ,pp. : 2131-2136

Informa Healthcare

Access to resources Recommend Favorite

Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial

By  

Psychotherapy and Psychosomatics, Vol. 81, Iss. 5, 2012-08 ,pp. : 312-314

Karger

Access to resources Recommend Favorite